Neuralink
Founded in 2016, based in Fremont, CA, it employs around 500 people. It operates in HealthTech, Therapeutic Devices, Neurologial Diagnostics and Artificial Intelligence. Neuralink is led by a world-class interdisciplinary team of neuroscientists, engineers, AI scientists, and robotics experts.
What is Neuralink?
Neuralink is a neurotechnology company co-founded by Elon Musk in 2016, who invested $100 million in the company. Its primary aim is to develop implantable brain–machine interfaces (BMIs), which are devices that establish direct communication between the brain and external devices.
The company sells a solution formed by: the operating robot R1, the N1 implant, the N1 charger and the Neuralink Application.
Key Objectives
Medical Applications
Treat neurological conditions such as Parkinson's disease, epilepsy, and paralysis.
Restore sensory or motor function for individuals with disabilities.
Restore view to cure blindness.
Address mental health conditions, such as depression and anxiety.
Human Enhancement
Enable humans to merge with artificial intelligence (AI) by integrating neural implants, potentially improving cognitive abilities.
Facilitate advanced human–computer interaction, like controlling devices through thoughts.
Long-Term Vision
Allow seamless brain–computer communication to enhance memory, learning, and overall neural efficiency.
Create symbiosis between humans and AI to ensure humanity's relevance in an AI-dominated future.
Core Technology
Neural Implants: Small, flexible threads equipped with electrodes inserted into the brain using a custom-built robotic system.
BCI Chip: A microchip that processes and transmits brain signals to external devices via Bluetooth or other wireless technologies.
Robot-Assisted Surgery: Highly precise surgical robots insert the threads into the brain, minimizing tissue damage.
Status and Challenges
Developed a minimally viable product consisting of electrode threads, an implantable chip, and a surgical robot. Neuralink received FDA approval for human trials in May 2023 and implanted its device in the first human patient in January 2024. Has embedded 3 patients to date as of Q1 2025.
Neuralink has conducted preclinical trials on animals and obtained FDA approval in 2023 to start human trials for addressing conditions like paralysis.
The company faces significant technical, ethical, and regulatory challenges, including risks of brain surgery, long-term implant viability, and concerns about privacy and misuse of brain data.
Business Development
2016: Neuralink founded
Aug 2020: Live demonstration of pigs with Neuralink implants, showcasing real-time neural activity
2021 – 2023: Data trials in monkeys
May 2023: Received FDA approval to commence human trials
Jan 2024: First-in-human implant
Aug 2024: Second implant, successful functional use (playing video games hands-free)
Jan 2025: Third patient implanted with ALS
2025 (H2): Expansion to 20–30 patients (regulatory traction)
2026 – 2027: Planned regulatory filings & pathway to commercial launch
2030+: Long-term vision – Mass-market neuro-enhancement devices in healthy humans
Key Investors
Funders Fund, GigaFund, Elon Musk, Valor Equity Partners and GV
Neuralink Stock
Stock price source: IPO CLUB Valuation at Market© - Become a member for in-depth coverage
Neuralink remains a privately held company, which means its stock isn't available for public trading on major stock exchanges like the NYSE or NASDAQ. However, investors can explore investment opportunities through platforms like IPO CLUB, where they can gain access to shares in private companies like Neuralink.
Most Recent Financing Status
Neuralink is continuing to raise capital following its Series D round, which closed in August 2023 with $280 million led by Peter Thiel’s Founders Fund. The company quietly secured an additional $43 million in November 2023, bringing the total for the Series D to $323 million and its total funding to $680 million to date. Current fundraising are ongoing for new round that could value the company at a $9 billion post-money valuation.
Neuralink Latest News
Stay up-to-date with all the latest news about Neuralink stock, the IPO, and investment opportunities. By clicking here, you'll access real-time updates and in-depth analysis from market experts, empowering you to make informed decisions about your investment journey. Whether you're a seasoned investor or just getting started, our platform is tailored to provide you with all the crucial information you need to navigate the thrilling world of the stock market and IPOs. Dive in and keep your finger on the pulse of the financial markets.
Neuralink is developing a fully-implanted, wireless, high-channel count brain-machine interface (BMI) with the goal of enabling people with paralysis to directly use their neural activity to operate computers and mobile devices with speed and ease.
Neuralink has launched its CONVOY study, testing its brain-computer interface (BCI) for controlling assistive robotic devices. The study’s first participant, Alex, who is paralyzed from the neck down, previously used Neuralink’s BCI to design graphics telepathically. Now, he will explore controlling a robotic arm, marking a major step in assistive tech.